Kerendia (Finerenone, BAY94-8862)

DRUG3 trials

Sponsors

Bayer, Peter Rossing

Conditions

Cardiovascular Autonomic NeuropathyChronic Kidney DiseaseDiabetic NeuropathiesType 2 DiabetesType 2 Diabetes Mellitus

Phase 2

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

RecruitingNCT06906081

Peter RossingCardiovascular Autonomic Neuropathy, Diabetic Neuropathies, Type 2 Diabetes

Start: 2025-05-02End: 2028-01-31Target: 100Updated: 2025-05-25

Unknown Phase

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Active, not recruitingNCT05348733

BayerChronic Kidney Disease, Type 2 Diabetes Mellitus

Start: 2022-06-13End: 2026-12-22Updated: 2026-06-26

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

RecruitingNCT07232537

BayerChronic Kidney Disease, Type 2 Diabetes Mellitus

Start: 2025-11-20End: 2028-01-28Target: 500Updated: 2026-06-15

Related Papers

Protocol for the FibroCAN study: a randomised controlled trial of finerenone treatment for early-stage cardiovascular autonomic neuropathy in type 2 diabetes.

2025-10-23

Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.

2025-10-06

First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting

Journal of Nephrology2024-09-2814 citations

Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.

2023-02-0218 citations